Response to induction therapy
| . | Newly diagnosed . | . | Relapses* . | Oral ATRA Failure† . | Total . | |
|---|---|---|---|---|---|---|
| Group 1 . | Group 2 . | |||||
| Intent-to-treat patients | ||||||
| n = 32 | n = 35 | n = 20 | n = 15 | n = 2 | n = 69 | |
| No. remission (%) | 20 (62%) | 17 (49%) | 14 (70%) | 3 (20%) | 1 (50%) | 38 (57%) |
| Early death | 12 | 8 | 2 | 6 | 0 | 20 |
| Resistant | 0 | 10 | 4 | 6 | 1 | 11 |
| Evaluable patients | ||||||
| n = 23 | n = 31 | n = 18 | n = 13 | n = 2 | n = 56 | |
| No. remission (%) | 20 (87%) | 17 (55%) | 14 (71%) | 3 (23%) | 1 (50%) | 38 (63%) |
| Early death | 3 | 6 | 2 | 4 | 0 | 9 |
| Resistant | 0 | 8 | 2 | 6 | 1 | 9 |
| . | Newly diagnosed . | . | Relapses* . | Oral ATRA Failure† . | Total . | |
|---|---|---|---|---|---|---|
| Group 1 . | Group 2 . | |||||
| Intent-to-treat patients | ||||||
| n = 32 | n = 35 | n = 20 | n = 15 | n = 2 | n = 69 | |
| No. remission (%) | 20 (62%) | 17 (49%) | 14 (70%) | 3 (20%) | 1 (50%) | 38 (57%) |
| Early death | 12 | 8 | 2 | 6 | 0 | 20 |
| Resistant | 0 | 10 | 4 | 6 | 1 | 11 |
| Evaluable patients | ||||||
| n = 23 | n = 31 | n = 18 | n = 13 | n = 2 | n = 56 | |
| No. remission (%) | 20 (87%) | 17 (55%) | 14 (71%) | 3 (23%) | 1 (50%) | 38 (63%) |
| Early death | 3 | 6 | 2 | 4 | 0 | 9 |
| Resistant | 0 | 8 | 2 | 6 | 1 | 9 |
Group 1: includes first-relapse patients who had not received oral all-trans retinoic acid (ATRA) for at least 1 year before relapse and 4 ATRA naive relapses. All ATRA naive patients achieved CR. Group 2: second or subsequent remission or in first relapse but received ATRA within 1 year before enrollment.
These 2 patients were newly diagnosed who had failed oral ATRA and were switched to the liposomal form.